AstraZeneca is an England-based pharmaceutical firm that develops and commercializes prescription medicines to the treatment of a range of diseases such as oncology and renal.
Business Model:
Revenue: $41.5B
Employees: 10,001-999,999
Address: 1 Francis Crick Avenue
City: Cambridge
State: england
Zip: CB2 0RE
Country: GB
AstraZeneca is an England-based pharmaceutical firm that develops and commercializes prescription medicines to the treatment of a range of diseases such as oncology and renal.
Contact Phone:
Contact Email:
Listed Exchange:
NYSE
IPO Date:
5/4/2001
Ticker Symbol:
AZN
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2022 | Yueer Gene | Series B | 0 |
11/2014 | MdBio Foundation | Grant | 500k |
2/2018 | Rani Therapeutics | Venture Round | 0 |
8/2016 | Moderna Therapeutics | Series F | 474M |
2/2014 | Ashland-Boyd County Health Department | Grant | 213k |
3/2022 | Huma | Corporate Round | 0 |
2/2014 | Christiana Care Health Systems | Grant | 213.1k |
2/2018 | Viela Bio | Series A | 0 |
2/2014 | ELVPHD | Grant | 250k |
2/2014 | Matthew Walker Comprehensive Health Center | Grant | 173.2k |
12/2022 | GenAssist Therapeutics | Series A | - |
8/2017 | ETHRIS | Corporate Round | 29.5M |
10/2017 | ADC Therapeutics | Series E | 0 |
10/2016 | ADC Therapeutics | Series D | 0 |
8/2022 | Doctor.One | Grant | 87.2k |
7/2016 | FibroGen | Post-IPO Equity | 62M |
2/2014 | Sankofa Community Development Corporation | Grant | 150k |
2/2014 | Catherine’s Health Center | Grant | 163.4k |
11/2022 | ZSHK Laboratories | Series B | 12.5M |
2/2014 | The Health Wagon | Grant | 200k |
10/2018 | Innate Pharma | Corporate Round | 0 |
2/2014 | Allegiance Health Foundation | Grant | 157k |
9/2017 | Rani Therapeutics | Series D | 39M |
3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
9/2015 | ADC Therapeutics | Series C | 0 |
8/2022 | Yunjian | Series B | - |
8/2013 | Nektar Therapeutics | Post-IPO Equity | 25M |
2/2014 | The Food Trust | Grant | 209.8k |
2/2014 | Mallory Community Health Center | Grant | 228.4k |
2/2014 | Manna Ministries | Grant | 152.8k |
6/2019 | ADC Therapeutics | Series E | 0 |
2/2014 | Whittier Street Health Center | Grant | 150.8k |
2/2014 | North Georgia Healthcare Center | Grant | 175.2k |
2/2014 | UnityPoint Health | Grant | 187.3k |
1/2015 | Moderna Therapeutics | Series E | 0 |
9/2021 | Cellular Biomedicine Group | Series A | 0 |
9/2018 | PhaseBio Pharmaceuticals | Series D | 0 |
11/2022 | Rgenta Therapeutics | Series A | 0 |
9/2020 | OnDosis | Seed Round | 0 |
2/2014 | UCHealth | Grant | 154.3k |
8/2022 | Doctor.One | Grant | 0 |
6/2022 | Yueer Gene | Series B | 0 |
3/2022 | Huma | Corporate Round | 0 |
9/2021 | Cellular Biomedicine Group | Series A | 0 |
9/2020 | OnDosis | Seed Round | 0 |
6/2019 | ADC Therapeutics | Series E | 0 |
10/2018 | Innate Pharma | Corporate Round | 0 |
9/2018 | PhaseBio Pharmaceuticals | Series D | 0 |
2/2018 | Viela Bio | Series A | 0 |
2/2018 | Rani Therapeutics | Venture Round | 0 |
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2022 | Investment Fund | $100M |
---|
Announced Date | Name | Price |
---|---|---|
7/2022 | TeneoTwo | |
9/2021 | Caelum Biosciences | |
12/2020 | Alexion Pharmaceuticals | |
4/2016 | Takeda Respiratory Business | |
12/2015 | AcertaPharma | |
11/2015 | ZS Pharma | |
7/2014 | Almirall | |
6/2013 | Pearl Therapeutics | |
5/2013 | Omthera Pharmaceuticals | |
4/2012 | Ardea Biosciences |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|